Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)

R. Gopalakrishnan, U. Hedner, S. Ghosh, R. C. Nayak, T. C. Allen, U. R. Pendurthi, L. V M Rao

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Recent clinical studies suggest that the prophylactic use of recombinant factor VIIa (rFVIIa) markedly reduces the number of bleeding episodes in hemophilic patients with inhibitors. Given the short biological half-life of rFVIIa, it is unclear how rFVIIa could be effective in prophylactic treatment. Objectives: To examine the extravascular distribution of pharmacologically administered rFVIIa to obtain clues on how rFVIIa could work in prophylaxis. Methods: Recombinant mouse FVIIa tagged with AF488 fluorophore (AF488-FVIIa) was administered into mice via the tail vein. At different time intervals following the administration, mice were exsanguinated and various tissues were collected. The tissue sections were processed for immunohistochemistry to evaluate distribution of rFVIIa. Results: rFVIIa, immediately following the administration, associated with the endothelium lining of large blood vessels. Within 1 h, rFVIIa bound to endothelial cells was transferred to the perivascular tissue surrounding the blood vessels and thereafter diffused throughout the tissue. In the liver, rFVIIa was localized to sinusoidal capillaries and accumulated in hepatocytes. In bone, rFVIIa was accumulated in the zone of calcified cartilage and some of it was retained there for a week. The common finding of the present study is that rFVIIa in extravascular spaces was mostly localized to regions that contain TF expressing cells. Conclusions: The present study demonstrates that pharmacologically administered rFVIIa readily associates with the vascular endothelium and subsequently enters into extravascular spaces where it is likely to bind to TF and is retained for extended time periods. This may explain the prolonged pharmacological effect of rFVIIa.

Original languageEnglish (US)
Pages (from-to)301-310
Number of pages10
JournalJournal of Thrombosis and Haemostasis
Volume8
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

recombinant FVIIa
Blood Vessels
Vascular Endothelium
Cartilage
Endothelium
Half-Life
Tail
Hepatocytes
Veins
Endothelial Cells
Immunohistochemistry
Pharmacology
Hemorrhage
Bone and Bones
Liver
Therapeutics
Clinical Studies

Keywords

  • Bio-distribution
  • Endothelial cell protein C receptor
  • Hemophilia
  • Prophylaxis
  • RFVIIa
  • Tissue factor

ASJC Scopus subject areas

  • Hematology

Cite this

Gopalakrishnan, R., Hedner, U., Ghosh, S., Nayak, R. C., Allen, T. C., Pendurthi, U. R., & Rao, L. V. M. (2010). Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). Journal of Thrombosis and Haemostasis, 8(2), 301-310. https://doi.org/10.1111/j.1538-7836.2009.03696.x

Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). / Gopalakrishnan, R.; Hedner, U.; Ghosh, S.; Nayak, R. C.; Allen, T. C.; Pendurthi, U. R.; Rao, L. V M.

In: Journal of Thrombosis and Haemostasis, Vol. 8, No. 2, 02.2010, p. 301-310.

Research output: Contribution to journalArticle

Gopalakrishnan, R, Hedner, U, Ghosh, S, Nayak, RC, Allen, TC, Pendurthi, UR & Rao, LVM 2010, 'Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)', Journal of Thrombosis and Haemostasis, vol. 8, no. 2, pp. 301-310. https://doi.org/10.1111/j.1538-7836.2009.03696.x
Gopalakrishnan, R. ; Hedner, U. ; Ghosh, S. ; Nayak, R. C. ; Allen, T. C. ; Pendurthi, U. R. ; Rao, L. V M. / Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). In: Journal of Thrombosis and Haemostasis. 2010 ; Vol. 8, No. 2. pp. 301-310.
@article{64b00bc1f60b4978af06592cb24ba2a0,
title = "Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)",
abstract = "Background: Recent clinical studies suggest that the prophylactic use of recombinant factor VIIa (rFVIIa) markedly reduces the number of bleeding episodes in hemophilic patients with inhibitors. Given the short biological half-life of rFVIIa, it is unclear how rFVIIa could be effective in prophylactic treatment. Objectives: To examine the extravascular distribution of pharmacologically administered rFVIIa to obtain clues on how rFVIIa could work in prophylaxis. Methods: Recombinant mouse FVIIa tagged with AF488 fluorophore (AF488-FVIIa) was administered into mice via the tail vein. At different time intervals following the administration, mice were exsanguinated and various tissues were collected. The tissue sections were processed for immunohistochemistry to evaluate distribution of rFVIIa. Results: rFVIIa, immediately following the administration, associated with the endothelium lining of large blood vessels. Within 1 h, rFVIIa bound to endothelial cells was transferred to the perivascular tissue surrounding the blood vessels and thereafter diffused throughout the tissue. In the liver, rFVIIa was localized to sinusoidal capillaries and accumulated in hepatocytes. In bone, rFVIIa was accumulated in the zone of calcified cartilage and some of it was retained there for a week. The common finding of the present study is that rFVIIa in extravascular spaces was mostly localized to regions that contain TF expressing cells. Conclusions: The present study demonstrates that pharmacologically administered rFVIIa readily associates with the vascular endothelium and subsequently enters into extravascular spaces where it is likely to bind to TF and is retained for extended time periods. This may explain the prolonged pharmacological effect of rFVIIa.",
keywords = "Bio-distribution, Endothelial cell protein C receptor, Hemophilia, Prophylaxis, RFVIIa, Tissue factor",
author = "R. Gopalakrishnan and U. Hedner and S. Ghosh and Nayak, {R. C.} and Allen, {T. C.} and Pendurthi, {U. R.} and Rao, {L. V M}",
year = "2010",
month = "2",
doi = "10.1111/j.1538-7836.2009.03696.x",
language = "English (US)",
volume = "8",
pages = "301--310",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)

AU - Gopalakrishnan, R.

AU - Hedner, U.

AU - Ghosh, S.

AU - Nayak, R. C.

AU - Allen, T. C.

AU - Pendurthi, U. R.

AU - Rao, L. V M

PY - 2010/2

Y1 - 2010/2

N2 - Background: Recent clinical studies suggest that the prophylactic use of recombinant factor VIIa (rFVIIa) markedly reduces the number of bleeding episodes in hemophilic patients with inhibitors. Given the short biological half-life of rFVIIa, it is unclear how rFVIIa could be effective in prophylactic treatment. Objectives: To examine the extravascular distribution of pharmacologically administered rFVIIa to obtain clues on how rFVIIa could work in prophylaxis. Methods: Recombinant mouse FVIIa tagged with AF488 fluorophore (AF488-FVIIa) was administered into mice via the tail vein. At different time intervals following the administration, mice were exsanguinated and various tissues were collected. The tissue sections were processed for immunohistochemistry to evaluate distribution of rFVIIa. Results: rFVIIa, immediately following the administration, associated with the endothelium lining of large blood vessels. Within 1 h, rFVIIa bound to endothelial cells was transferred to the perivascular tissue surrounding the blood vessels and thereafter diffused throughout the tissue. In the liver, rFVIIa was localized to sinusoidal capillaries and accumulated in hepatocytes. In bone, rFVIIa was accumulated in the zone of calcified cartilage and some of it was retained there for a week. The common finding of the present study is that rFVIIa in extravascular spaces was mostly localized to regions that contain TF expressing cells. Conclusions: The present study demonstrates that pharmacologically administered rFVIIa readily associates with the vascular endothelium and subsequently enters into extravascular spaces where it is likely to bind to TF and is retained for extended time periods. This may explain the prolonged pharmacological effect of rFVIIa.

AB - Background: Recent clinical studies suggest that the prophylactic use of recombinant factor VIIa (rFVIIa) markedly reduces the number of bleeding episodes in hemophilic patients with inhibitors. Given the short biological half-life of rFVIIa, it is unclear how rFVIIa could be effective in prophylactic treatment. Objectives: To examine the extravascular distribution of pharmacologically administered rFVIIa to obtain clues on how rFVIIa could work in prophylaxis. Methods: Recombinant mouse FVIIa tagged with AF488 fluorophore (AF488-FVIIa) was administered into mice via the tail vein. At different time intervals following the administration, mice were exsanguinated and various tissues were collected. The tissue sections were processed for immunohistochemistry to evaluate distribution of rFVIIa. Results: rFVIIa, immediately following the administration, associated with the endothelium lining of large blood vessels. Within 1 h, rFVIIa bound to endothelial cells was transferred to the perivascular tissue surrounding the blood vessels and thereafter diffused throughout the tissue. In the liver, rFVIIa was localized to sinusoidal capillaries and accumulated in hepatocytes. In bone, rFVIIa was accumulated in the zone of calcified cartilage and some of it was retained there for a week. The common finding of the present study is that rFVIIa in extravascular spaces was mostly localized to regions that contain TF expressing cells. Conclusions: The present study demonstrates that pharmacologically administered rFVIIa readily associates with the vascular endothelium and subsequently enters into extravascular spaces where it is likely to bind to TF and is retained for extended time periods. This may explain the prolonged pharmacological effect of rFVIIa.

KW - Bio-distribution

KW - Endothelial cell protein C receptor

KW - Hemophilia

KW - Prophylaxis

KW - RFVIIa

KW - Tissue factor

UR - http://www.scopus.com/inward/record.url?scp=74749095228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749095228&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2009.03696.x

DO - 10.1111/j.1538-7836.2009.03696.x

M3 - Article

C2 - 19943873

AN - SCOPUS:74749095228

VL - 8

SP - 301

EP - 310

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 2

ER -